Navigation Links
STAAR Surgical Reports 14% Fourth Quarter Revenue Growth
Date:3/16/2009

Cash Used for Operating Activities Declines to Less Than $1 Million

Gross Margin Increases to 57.1%

Programs Implemented to Yield Additional Cost Savings During 2009 & 2010

First Quarter Sales Off to Strong Start

MONROVIA, Calif., March 16 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported financial results for the fourth quarter and full year ended January 2, 2009. The financial results for both periods include the operating performance of STAAR Japan, which STAAR acquired at the beginning of fiscal year 2008.

Fourth Quarter Highlights

Financial Highlights

  • Total sales grew 14% year-over-year to $18.2 million due to strong sales of STAAR Japan of $3.7 million; 19% growth excluding impact of currency; total sales excluding Japan declined 9%
  • International sales grew 23% year-over-year, 30% excluding impact of currency
  • U.S. sales declined by 6% while operating expenses, excluding other charges, declined by 21%
  • Gross margin improved 700 basis points from the year ago period to 57.1%
  • Operating loss increased by 127% due to patent impairment charge and litigation verdict, reduced by 41%, excluding these other operating expenses
  • Cash used for operating activities during the quarter, including Japan, decreased to $991,000 and $514,000 excluding Japan; legal costs paid during the quarter total $600,000

"Our fourth quarter performance, though below our original expectations, capped a year of significant achievements for STAAR Surgical," said Barry G. Caldwell, President and CEO. "For the full year, we grew revenue 26%, increased gross margin by more than 600 basis points excluding acquisition accounting charges and reduced cash used for operating activities by $6.4 million or 57%, excluding Japan. During the fourth quarter, we grew sales by 14%, reduced our cash burn from operations by approximately 81%, excluding Japan, to approximately $500,000 and implemented additional programs to enhance our profitability prospects in 2009. Though it is data for only the first two months of 2009, and we cannot be certain that current trends will continue, we have generated operating profits before non-cash charges during this period."

"At year's end we implemented a new U.S. sales force structure designed to maximize our Collamer material positioning for both ICLs and IOLs, as well as improve efficiencies. We expect that the implementation of this structure should yield us approximately $1 million in additional cost savings during 2009."

"Gross margin increased 700 basis points from the fourth quarter of 2007, and outside of Japan and excluding special charges we decreased year over year operating expenses by sixteen percent or $1.8 million," added Mr. Caldwell. "Our global Visian ICL fourth quarter sales declined slightly compared to the year ago period due primarily to two factors. First, we significantly reduced the practice of taking higher volume bulk sales during 2008 in the U.S. which was a larger factor in comparison to the fourth quarter of 2007. Also during the fourth quarter, our international distributors were all making efforts to reduce their inventory levels in this weakened economy as compared to their historical year-end inventory build. Aside from these two developments, our Visian ICL sales momentum remains strong and through the first two months both global and U.S. Visian ICL sales have grown in excess of 25% for the first quarter of 2009."

"We also continued to make progress with our IOL product line sales during the fourth quarter," Mr. Caldwell continued. "While total IOL sales increased 47% due to the strong contribution from Japan, our U.S. IOL sales decreased by only five percent as compared to a 26% decline in the fourth quarter of 2007. Our seven point plan to restore profitability to the US IOL business remains on track. In fact, at this point, we believe we are positioned to grow U.S. IOL sales in the first quarter as a result of our new NTIOL products and our new pricing strategy that assists doctors in this difficult economic environment."

"In addition, we have begun a Centers of Excellence project which is designed to take advantage of our key competencies in Japan and the U.S. In Japan the organization has demonstrated a real excellence in delivery systems for IOLs. Japan will become our Center of Excellence for lens delivery research and development. The U.S. organization has demonstrated an excellence in developing and manufacturing lens materials and designs. The U.S. will become our Center of Excellence for the manufacturing of lenses. Both of these moves should enhance our ability to introduce new technologies while reducing the cost of our IOLs significantly beginning in 2010.

"Our strong operational progress during the fourth quarter and first two months of 2009 has been overshadowed by the $4.9 million jury verdict in favor of Parallax Medical Systems, Inc. subsequent to year end. The next step in this case will be the formal entry of a judgment on the jury verdict by the judge hearing the case, which we expect will be completed before the end of March. We will use the 15-day filing extension for our 2008 10-K so that we can better assess the effects of the final judgment on our liquidity and capital resources," Mr. Caldwell concluded.

Financial Performance for the Fourth Quarter and Full Year Ended January 2, 2009

Total product sales for the quarter were $18.2 million, a 14% increase over the $15.9 million reported for the fourth quarter of 2007. The increase in sales was led by strong sales of STAAR Japan, which were $3.7 million in the quarter. Outside of Japan, international sales decreased 10% primarily due to changes in currency which negatively impacted international and total fourth quarter sales by $804,000 but also due to soft distributor sales of ICLs and IOLs. Total U.S. sales for the fourth quarter were $4.5 million, a six percent decrease from the fourth quarter of 2007. U.S. Visian ICL sales were $1.0 million, flat with the level recorded for the comparable period of 2007.

Total product sales for 2008 were $74.9 million, a 26% increase over the $59.4 million reported for 2007. The increase in sales was led by strong international product sales, which grew 41% and included $12.7 million in sales from STAAR Japan, which exceeded the Company's goal for this market. Outside of Japan, total international product sales grew 9% due to the $1.6 million favorable effect of currency and a 26% increase in Visian ICL sales. Total U.S. sales for 2008 were $18.9 million, down four percent from $19.7 million in 2007. U.S. Visian ICL sales were $4.9 million, up 18% over $4.1 million in 2007.

Gross profit margin for the fourth quarter was 57.1%, compared to 50.1% in the fourth quarter of 2007. Gross profit margin for 2008 was 53.6%, compared with 49.3% for 2007. Excluding purchase accounting charges recorded in the first quarter of 2008, gross profit margin was 55.6% for the year. The significant improvement in gross profit margin for the quarter is due to sales of preloaded IOLs in Japan, which yield higher average selling prices than in other countries. The improvement for the year is due to increased sales of Visian ICL and TICLs and sales of preloaded IOLs in Japan. Each one of STAAR's reporting sales entities increased its gross margin percentage for the year as compared to 2007.

General and administrative expenses for the quarter were $4.3 million, representing a 27% increase over the $3.4 million incurred in the fourth quarter of 2007. The increase was due to incremental G&A costs of STAAR Japan of $1.1 million. Otherwise, G&A expenses were flat to Q4 of 2007. General and administrative expenses for 2008 were $15.7 million, representing a 21% increase over the $13.0 million incurred in 2007. The increase resulted from incremental G&A costs of STAAR Japan of $3.7 million, partially offset by decreased costs in the U.S.

Marketing and selling expenses for the fourth quarter were $6.4 million, a one percent decrease from the fourth quarter of 2007. The decrease was due to lower expenses in the U.S., Europe and Australia offset by the incremental costs of STAAR Japan of $1.2 million. Marketing and selling expenses for 2008 were $27.1 million (including $4.1 million for Japan), representing a 14% increase over the $23.7 million incurred in 2007. Changes in currency had a $295,000 favorable effect on marketing and selling expenses for the quarter and a $560,000 unfavorable effect for the full year 2008.

Research and development expenses for the quarter were $2.0 million, including $637,000 for Japan, which represents a 15% increase over the $1.7 million incurred in the fourth quarter of 2007. Research and development expenses for 2008 were $7.9 million, which represents an 18% increase over the $6.7 million incurred in 2007. The increase is due to the incremental costs of STAAR Japan ($2.2 million), partially offset by cost reductions in the U.S.

Included in other operating expenses for the quarter is a $1 million non-cash expense associated with the impairment of certain patents which have been determined to have minimal fair value and a reserve of $4.9 million for the jury verdict in favor of Parallax Medical Systems, Inc. subsequent to year end. Also included in other operating expenses for the full year is the $3,850,000 loss on settlement of preexisting distribution arrangement recorded in connection with the purchase of STAAR Japan.

For the quarter ended January 2, 2009, net loss was $9.5 million or $0.32 per share, compared with $4.3 million or $0.15 for the fourth quarter of 2007. The per share loss associated with the patent impairment charge and the jury verdict was $0.03 and $0.17, respectively. Non-cash expenses for the quarter were $2.6 million. For the year ended January 2, 2009, the net loss was $23.2 million or $0.79 per share, compared with $16.0 million or $0.57 for the year ended December 28, 2007. The net loss per share associated with other operating expenses was $0.38. Total non-cash expenses, including those associated with STAAR Japan were $11.0 million during 2008, versus $2.1 million during 2007.

At January 2, 2009, cash and cash equivalents were $5.0 million, compared to $10.9 million at December 28, 2008. During the quarter the Company used $991,000 of cash for operating activities compared with $3.4 million in the first quarter of 2008, $2.8 million in the second quarter of 2008 and $1.1 million in third quarter of 2008 and $1.7 million in the fourth quarter of 2007. Cash used in operating activities for the year ended January 2, 2009 was $8.2 million compared with the $11.2 million reported for the prior year. STAAR Japan used $477,000 and $3.4 million in cash for operating activities for the three and 12 months ended January 2, 2009, respectively. Excluding Japan, for the full year, cash used in operating activities has declined 58% from the amount used during 2007.

Conference Call

The Company will host a conference call and webcast on Monday, March 16, 2009 at 4:30 p.m. Eastern Time to discuss the Company's fourth quarter and current corporate developments. The dial-in number for the conference call is 800-218-0713 for domestic participants and 303-262-2052 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using passcode 11125535#. To access the live webcast of the call, go to STAAR Surgical's website at www.staar.com. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. Collamer(R) is the brand name for STAAR's proprietary collagen copolymer lens material. More information is available at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: projections of earnings, revenue, sales, cash or other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; strategies or objectives; prospects for appeal of the adverse verdict in the Parallax litigation; continued growth of the ICL, TICL or other products in the U.S. or international markets; expected cost savings; our future performance; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the need to satisfy the forthcoming judgment in the Parallax case or post an appeal bond and the resulting effect on our liquidity, our limited capital resources and limited access to financing, the need to defend other litigation similar to the Parallax case and to satisfy judgment in the event of an adverse ruling in that case, for which we have taken no reserve, the effect the global recession may have on sales of products, especially products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that we will not succeed in introducing improved products that restore the profitability of our U.S. IOL product line, our ability to resolve FDA concerns over the clinical study for the Toric ICL and to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the willingness of surgeons and patients to adopt a new product and procedure, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S.

STAAR currently lacks the cash to satisfy the judgment expected to result from the $4.9 million verdict in the Parallax case (the "Judgment"), or to fund the bond necessary to pursue appeal, and the court has not yet determined whether or for how long it will stay execution of the Judgment. If STAAR is unable to satisfy the Judgment or post an appeal bond before the expiration of any discretionary stay of the court, STAAR could be required to petition for protection under federal bankruptcy laws, which could further impair its financial position and liquidity, and would likely result in a default of its other debt obligations. STAAR assumes no obligation to update its forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

Use of Non-GAAP Information

This news release presents selected items from the Company's Condensed Consolidated Statements of Operations and Condensed Consolidated Statements of Cash Flows as reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and also on a non-GAAP basis after excluding data reported by STAAR Japan, excluding certain non-recurring expenses, and excluding changes in currency

The Company completed the acquisition of the remaining interests in STAAR Japan on December 29, 2007, the first day of its 2008 fiscal year. Prior to the acquisition, the Company reported its 50% ownership interest in STAAR Japan as an equity investment and did not incorporate STAAR Japan's financial data in the Company's financial statements. As a result, the Company's financial results in 2008 have been significantly affected by both non-recurring charges resulting from the accounting treatment of the transaction and by the consolidation of the results of STAAR Japan from the first quarter of 2008 forward. STAAR's management believes that it is important for investors to be able to identify the trends in its core business, including expense reduction, revenue enhancement and gross profit improvement, and that these trends can be discerned only by a comparison of 2007 financial data with non-GAAP 2008 data that excludes the newly added results from STAAR Japan. Since acquisition of the remaining interests in STAAR Japan, the Company's management has used this non-GAAP information internally to measure its progress compared to 2007 in achieving positive cash flow and returning to profitability. The Company's management currently believes that this information will enhance investors' overall understanding of its core performance when financial statements include comparisons to periods preceding the STAAR Japan acquisition. Going forward, the Company must achieve positive cash flow and profitability as a consolidated enterprise with STAAR Japan, and accordingly the Company cautions investors to consider both the GAAP financial statements as well as the non-GAAP financial information. The table below shows the following information from which this non-GAAP measure is derived: the statement of operations for STAAR Japan, Inc. in relevant periods, the statement of operations for the Company reported in accordance with GAAP for the same periods, and the effect of excluding the data for STAAR Japan, Inc.

When assessing the effectiveness of its initiatives to enhance long-term performance by reducing expenses, management may eliminate the effect of significant non-recurring expenses in order to discern underlying trends. In the 2008 fiscal year, the Company's results were significantly affected by the following non-recurring expenses classified as "other expense": a $1.5 million purchase accounting charge related to inventory purchased in the acquisition of STAAR Japan, Inc.; a $3.8 million charge for the settlement of a pre-existing distribution arrangement in connection with the STAAR Japan, Inc. acquisition, an impairment charge related to reversing the valuation of a patent from which STAAR does not expect to derive significant value, and the effect of an expected $4.9 million court judgment that will occur in 2009 but is accrued in fiscal year 2008. Because the effect of these charges can overwhelm the effect of meaningful trends in the Company's business performance, management considers both GAAP expenses and non-GAAP expenses excluding these non-recurring items. The Company believes that this non-GAAP expenses measure is also helpful to investors in discerning underlying trends. The following table shows the cumulative effect of the excluded non-recurring items.

The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on our results when reported in U.S. dollars. When preparing its financial statements in conformance with GAAP, the Company translates foreign currency sales and expenses to dollars at the weighted average of exchange rates in effect during the period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the "constant currency" rate to sales or expenses in the current period as well. Because changes in currency are outside of the control of the Company and its managers, management finds this non-GAAP measure useful in determining the long term progress of its initiatives and determining whether its managers are achieving their performance goals. The Company believes that the non-GAAP constant-currency sales results measures provided in this press release are similarly useful to investors to give insight on long term trends in the Company's performance without the external effect of changes in relative currency values. The table below shows sales results calculated in accordance with GAAP, the effect of currency, and the resulting non-GAAP measure expressed in constant currency.

    CONTACT:
    Investors                        Media
    EVC Group                        EVC Group
    Douglas Sherk, 415-896-6820      Christopher Gale 646-201-5431
    Michael Pollock, 415-896-5860

                              (Tables to Follow)


    STAAR Surgical Company
    Condensed Consolidated Statements of Operations
    (In 000's except for per share data)
    Unaudited

                               Three Months Ended            Year Ended
                               ------------------            ----------
                             January 2,  December 28,  January 2, December 28,
                                2009          2007        2009          2007
                                ----          ----        ----          ----

    Net sales                 $18,157       $15,885     $74,894       $59,363

    Cost of sales               7,797         7,921      34,787        30,097
                                -----         -----      ------        ------

    Gross profit               10,360         7,964      40,107        29,266
                               ------         -----      ------        ------

      General and
       administrative:          4,289         3,370      15,730        12,951
      Marketing and selling     6,425         6,500      27,053        23,723
      Research and
       development              1,974         1,724       7,938         6,711
      Other operating
       expenses                 5,923             -       9,773             -
                                -----           ---       -----           ---

         Total selling, general
          and administrative
          expenses:            18,611        11,594      60,494        43,385
                               ------        ------      ------        ------

    Operating loss             (8,251)       (3,630)    (20,387)      (14,119)
                               ------        ------     -------       -------

    Other expense, net           (579)         (157)     (1,285)       (1,037)
                                 ----          ----      ------        ------

    Loss before provision
     (benefit) for
     income taxes              (8,830)       (3,787)    (21,672)      (15,156)

    Income tax provision
     (benefit)                    630           504       1,523           843
                                  ---           ---       -----           ---

    Net loss                  $(9,460)      $(4,291)   $(23,195)     $(15,999)
                              =======       =======    ========      ========


    Basic and diluted loss
     per share                 $(0.32)       $(0.15)     $(0.79)       $(0.57)
                               ======        ======      ======        ======


    Weighted average shares
     outstanding               29,496        29,388      29,474        28,121
                               ======        ======      ======        ======



    STAAR Surgical Company
    Global Sales
    (in 000's)
    Unaudited


                        Three Months Ended               Year Ended
                        ------------------               ----------

    Geographic       January  December            January  December
     Sales           2, 2009  28, 2007 % Change   2, 2009  28, 2007 % Change
                       ----      ----  --------   -------  -------- --------
    United States    $4,460    $4,730     -5.7%  $18,927   $19,721     -4.0%

    Germany           5,864     6,260     -6.3%   25,124    23,731      5.9%
    Japan             3,878       141   2650.4%   13,485       423   3087.9%
    Other             3,955     4,754    -16.8%   17,358    15,488     12.1%
                      -----     -----             ------    ------
    Total
     International
     Sales           13,697    11,155     22.8%   55,967    39,642     41.2%

                    -------   -------            -------   -------
        Total
         Sales      $18,157   $15,885     14.3%  $74,894   $59,363     26.2%
                    =======   =======            =======   =======


    Product Sales
        IOLs         $8,550    $5,816     47.0%  $32,926   $23,379     40.8%
        ICLs         $4,389    $4,639     -5.4%  $19,069   $15,368     24.1%
        Other         5,218     5,430     -3.9%   22,899    20,616     11.1%
                      -----     -----             ------    ------
      Total         $18,157   $15,885     14.3%  $74,894   $59,363     26.2%
                    =======   =======            =======   =======



    STAAR Surgical Company
    Condensed Consolidated Balance Sheets
    (in 000's)
    Unaudited

                                                    January 2,  December 28,
                                                       2009         2007
                                                       ----         ----
    Cash and cash equivalents                         $4,992      $10,895
    Short-term investments - restricted                  179          150
    Accounts receivable trade, net                     8,422        6,898
    Inventories                                       16,668       12,741
    Prepaids, deposits, and other current assets       2,009        1,610
                                                       -----        -----
       Total current assets                           32,270       32,294
                                                      ------       ------
    Property, plant, and equipment, net                5,974        5,772
    Intangible assets, net                             5,611        3,959
    Goodwill                                           7,538        7,534
    Advance payment for acquisition of Canon Staar         -        4,000
    Other assets                                       1,189          620
                                                       -----          ---
       Total assets                                  $52,582      $54,179
                                                     =======      =======


    Accounts payable                                  $6,626       $4,823
    Deferred income taxes - current                      282          102
    Obligations under capital leases - current           989          822
    Line of credit                                     2,200            -
    Other current liabilities                         11,366        5,541
                                                      ------        -----
       Total current liabilities                      21,463       11,288
                                                      ------       ------
    Notes payable - long-term, net of discount         4,414        4,166
    Obligations under capital leases - long-term         897        1,311
    Deferred income taxes - long-term                  1,335          570
    Other long-term liabilities                        1,678          619
                                                       -----          ---
       Total liabilities                              29,787       17,954
                                                      ------       ------

    Series A redeemable convertible preferred
     stock                                             6,768            -

    Stockholders' equity - net                        16,027       36,225
                                                      ------       ------
       Total liabilities, redeemable convertible
        preferred stock and equity                   $52,582      $54,179
                                                     =======      =======



    STAAR Surgical Company
    Condensed Consolidated Statements of Cash Flows
    (in 000's)
    Unaudited
                                                            Year Ended
                                                            ----------
                                                      January 2,  December 28,
                                                         2009         2007
                                                         ----         ----
    Cash flows from operating activities:
     Net loss                                          $(23,195)     $(15,999)
     Adjustments to reconcile net loss to net cash
      used in operating activities:
      Depreciation of property, plant and equipment       2,797         2,001
      Amortization of intangibles                         1,866           481
      Amortization of discount                              248            26
      Loss on extinguishment of debt                          -           215
      Fair value adjustment of warrant                       (7)         (182)
      Loss on disposal of property and equipment             48           307
      Equity in operations of joint venture                   -           280
      Deferred income tax                                   238           493
      Stock-based compensation expense                    1,513         1,456
      Common stock issued for services                        -           125
      Loss on settlement of pre-existing
       distribution arrangement                           3,850             -
      Change in pension accounting                           72           179
      Other                                                 151            32
    Changes in working capital:
      Accounts receivable                                  (891)         (210)
      Inventories                                         1,125           861
      Prepaids, deposits and other current assets           708           330
      Accounts payable                                   (1,870)         (637)
      Other current liabilities                           5,119          (942)
                                                           -----          ----
            Net cash used in operating activities        (8,228)      (11,184)
                                                         ------       -------

    Cash flows from investing activities:
      Cash acquired in acquisition of Canon Staar,
       net of acquisition costs                           2,215             -
      Advance payment on acquisition of Canon Staar
       Joint Venture                                          -        (4,000)
      Deferred acquisition costs of Canon Staar               -          (197)
      Acquisition of property, plant and equipment       (1,092)         (691)
      Proceeds from sale of property, plant and
       equipment                                            167            72
      Purchase of short-term investments                   (212)            -
      Dividend received from joint venture                    -           117
      Net change in other assets                             43            24
                                                             --            --
            Net cash provided by (used in) investing
             activities                                   1,121        (4,675)
                                                          -----        ------

    Cash flows from financing activities:
      Proceeds from notes payable                             -         9,000
      Repayments of notes payable                             -        (4,000)
      Repayment of note issued in connection with
       purchase of minority interest in subsidiary            -          (972)
      Borrowings under lines of credit                    3,880         1,812
      Repayments of lines of credit                      (1,940)       (3,610)
      Repayment of capital lease lines of credit           (983)         (692)
      Net proceeds from the public sale of equity
       securities                                             -        16,613
      Proceeds from the exercise of stock options            40           584
                                                             --           ---
            Net cash provided by financing activities       997        18,735
                                                            ---        ------

    Effect of exchange rate changes on cash and cash
     equivalents                                            207           261
                                                            ---           ---

    (Decrease) increase in cash and cash equivalents     (5,903)        3,137
    Cash and cash equivalents, at beginning of the
     period                                              10,895         7,758
                                                         ------         -----
    Cash and cash equivalents, at end of the period      $4,992       $10,895
                                                         ======       =======



    STAAR Surgical Company
    GAAP Reconciliation Table
    2-Jan-09

                                           Q4 2008
                                           -------
                                                               Ex-
                                                              Japan
    Statement of                                   Other       and
     Operations          As Reported    Japan     Expenses    Other   Q4 2007
                         -----------    -----    ---------   ------   -------
    Sales                    $18,157    $3,678          $-   $14,479  $15,885
    Cost of Sales              7,797       968           -     6,829    7,922
    Gross Profit              10,360     2,710           -     7,650    7,963
    Gross Profit Margin         57.1%     73.7%        0.0%     52.8%    50.1%
    General and
     Administrative            4,289     1,091           -     3,198    3,370
    Marketing and
     Selling                   6,425     1,165           -     5,260    6,500
    Research and
     Development               1,974       637           -     1,337    1,724
    Other Operating
     Expenses                  5,923         -       5,923         -        -
    Total Selling,
     General,
     and Administrative       18,611     2,893       5,923     9,795   11,594
    Operating Loss            (8,251)     (183)     (5,923)   (2,145)  (3,631)
    Other Expense, Net          (579)      (79)          -      (500)    (157)
    Loss Before Income
     Taxes                    (8,830)     (262)     (5,923)   (2,645)  (3,788)
    Income Tax Provision
     (Benefit)                   630      (268)          -       898      504
    Net Loss                 $(9,460)       $6     $(5,923)  $(3,543) $(4,292)
    Loss Per Share            $(0.32)       $-      $(0.20)   $(0.12)  $(0.15)



                                           2008 vs. 2007
                                           -------------
                                As Reported             Ex-Japan
                                -----------             --------
    Statement of
     Operations              $ Change   % Change   $ Change   % Change
                             --------   --------   --------   --------
    Sales                     $2,272        14%    $(1,406)       -9%
    Cost of Sales               (125)       -2%     (1,093)      -14%
    Gross Profit               2,397        30%       (313)       -4%
    Gross Profit Margin          6.9%       14%        2.7%        5%
    General and
     Administrative              919        27%       (172)       -5%
    Marketing and
     Selling                     (75)       -1%     (1,240)      -19%
    Research and
     Development                 250        15%       (387)      -22%
    Other Operating
     Expenses                  5,923         0%          -         0%
    Total Selling,
     General,
     and Administrative        7,017        61%     (1,799)      -16%
    Operating Loss            (4,620)      127%      1,486       -41%
    Other Expense, Net          (422)      269%       (343)      218%
    Loss Before Income
     Taxes                    (5,042)      133%      1,143       -30%
    Income Tax Provision
     (Benefit)                   126        25%        394        78%
    Net Loss                 $(5,168)      120%       $749       -17%
    Loss Per Share            $(0.17)      120%      $0.03       -18%



                                           2008
                                           ----
    Statement of                                  Other     Ex-Japan
     Operations          As Reported   Japan     Expenses   and Other   2007
                         -----------   -----    ---------   ---------   ----
    Sales                    $74,894  $12,731          $-   $62,163   $59,363
    Cost of Sales             34,787    3,711       1,524    29,552    30,097
    Gross Profit              40,107    9,020      (1,524)   32,611    29,266
    Gross Profit Margin         53.6%    70.9%        0.0%     52.5%     49.3%
    General and
     Administrative           15,730    3,690           -    12,040    12,951
    Marketing and
     Selling                  27,053    4,098           -    22,955    23,723
    Research and
     Development               7,938    2,164           -     5,774     6,711
    Other Operating
     Expenses                  9,773        -       9,773         -         -
    Total Selling,
     General, and
     Administrative           60,494    9,952       9,773    40,769    43,385
    Operating Loss           (20,387)    (932)    (11,297)   (8,158)  (14,119)
    Other Expense, Net        (1,285)    (103)          -    (1,182)   (1,037)
    Loss Before Income
     Taxes                   (21,672)  (1,035)    (11,297)   (9,340)  (15,156)
    Income Taxes               1,523     (268)          -     1,791       843
    Net Loss                $(23,195)   $(767)   $(11,297) $(11,131) $(15,999)
    Loss Per Share            $(0.79)  $(0.03)     $(0.38)   $(0.38)   $(0.57)


                                           2008 vs. 2007
                                           -------------
                                  As Reported           Ex-Japan
                                  -----------           --------
                             $ Change   % Change  $ Change  % Change
                             --------   --------  --------  --------
    Sales                     $15,531        26%   $2,800         5%
    Cost of Sales               4,690        16%     (545)       -2%
    Gross Profit               10,841        37%    3,345        11%
    Gross Profit Margin           4.3%        9%      3.2%        6%
    General and
     Administrative             2,779        21%     (911)       -7%
    Marketing and
     Selling                    3,330        14%     (768)       -3%
    Research and
     Development                1,227        18%     (937)      -14%
    Other Operating
     Expenses                   9,773         0%        -         0%
    Total Selling,
     General, and
     Administrative            17,109        39%   (2,616)       -6%
    Operating Loss             (6,268)       44%    5,961       -42%
    Other Expense, Net           (248)       24%     (145)       14%
    Loss Before Income
     Taxes                     (6,516)       43%    5,816       -38%
    Income Taxes                  680        81%      948       112%
    Net Loss                  $(7,196)       45%   $4,868       -30%
    Loss Per Share             $(0.22)       38%    $0.19       -34%



    Summary of Other
     Expenses Included
     in Statement of               Period
     Operations           Amount  Recorded
                          ------ ---------
    Purchase accounting
     charge related to
     inventory            $1,524     Q1
    Settlement of
     preexisting
     distribution
     arrangement           3,850     Q1
    Patent impairment
     charges               1,023     Q4
    Lawsuit verdict        4,900     Q4
                           -----
                         $11,297
                         =======




                                2008
                                ----
    Cash Flow          Q4       Japan   Ex-Japan
                       --       -----   --------
    Cash Used in
     Operating
     Activities         (991)     (477)     (514)
    Cash Provided
     by (Used in)
     Investing
     Activities         (541)     (178)     (363)
    Cash Provided
     by (Used in)
     Financing
     Activities         (161)       32      (193)
    Effect of
     Exchange on
     Cash                (12)      307      (319)
                         ---       ---      ----
    Increase
     (Decrease) in
     Cash             (1,705)     (316)   (1,389)
                      ======      ====    ======



                                        Q4 2008 vs. Q4 2007
                                        -------------------
                                  As Reported          Ex-Japan
                                  -----------          --------
    Cash Flow         2007   $ Change  % Change  $ Change  % Change
                      ----   --------  --------  --------  --------
    Cash Used in
     Operating
     Activities     (2,671)     1,680       -63%    2,157       -81%
    Cash Provided
     by (Used in)
     Investing
     Activities     (4,442)     3,901       -88%    4,079       -92%
    Cash Provided
     by (Used in)
     Financing
     Activities      3,780     (3,941)     -104%   (3,973)     -105%
    Effect of
     Exchange on
     Cash               32        (44)     -138%     (351)    -1097%
                        --        ---                ----
    Increase
     (Decrease) in
     Cash           (3,301)     1,596       -48%    1,912       -58%
                    ======      =====               =====




                                            2008
                                            ----
    Cash Flow                As Reported   Japan  Ex-Japan
                             -----------   -----  --------
    Cash Used in
     Operating
     Activities               (8,228)     (3,418)   (4,810)
    Cash Provided by
     (Used in) Investing
     Activities                1,121       2,624    (1,503)
    Cash Provided by
     (Used in) Financing
     Activities                  997       1,849      (852)
    Effect of Exchange
     on Cash                     207         499      (292)
                                 ---         ---      ----
    Increase (Decrease)
     in Cash                  (5,903)      1,554    (7,457)
                              ======       =====    ======


                                                2008 vs. 2007
                                                -------------
                                             As Reported          Ex-Japan
                                             -----------          --------
    Cash Flow                   2007    $ Change  % Change  $ Change  % Change
                                ----    --------  --------  --------  --------
    Cash Used in
     Operating
     Activities              (11,184)    2,956       -26%    6,374       -57%
    Cash Provided by
     (Used in) Investing
     Activities               (4,675)    5,796      -124%    3,172       -68%
    Cash Provided by
     (Used in) Financing
     Activities               18,735   (17,738)      -95%  (19,587)     -105%
    Effect of Exchange
     on Cash                     261       (54)      -21%     (553)     -212%
                                 ---       ---                ----
    Increase (Decrease)
     in Cash                   3,137    (9,040)     -288%  (10,594)     -338%
                               =====    ======             =======




                                       Q4 2008
                                       -------
                                       Effect
    Sales in Constant                    of
     Currency            As Reported  Currency  Ex-Currency
                         ----------- ---------  -----------
    US                         4,460         -        4,460
    International             13,697      (804)      14,501
                              ------      ----       ------
    Total                     18,157      (804)      18,961
                              ======      ====       ======


                                               Q4 2008 vs. Q4 2007
                                               -------------------
                                           As Reported           Ex-Currency
                                           -----------           -----------
    Sales in Constant
     Currency                   2007  $ Change   % Change  $ Change  % Change
                                ----  --------   --------  --------  --------
    US                         4,730       (270)       -6%     (270)      -6%
    International             11,155      2,542        23%    3,346       30%
                              ------
    Total                     15,885      2,272        14%    3,076       19%
                              ======



                                       2008
                                       ----

                                       Effect
    Sales in Constant                    of
     Currency            As Reported  Currency Ex-Currency
                         ----------- --------- -----------
    US                        18,927         -      18,927
    International             55,967     1,640      54,327
                              ------     -----      ------
    Total                     74,894     1,640      73,254
                              ======     =====      ======



                                                      2008 vs. 2007
                                                      -------------
                                             As Reported           Ex-Currency
                                             -----------           -----------
    Sales in Constant
     Currency                   2007    $ Change   % Change  $ Change % Change
                                ----    --------   --------  -------- --------
    US                        19,721         (794)       -4%     (794)    -4%
    International             39,642       16,325        41%   14,685      37%
                              ------
    Total                     59,363       15,531        26%   13,891     23%
                              ======



'/>"/>
SOURCE STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
2. STAAR Surgical Reports 33% Third Quarter Revenue Growth
3. STAAR Surgical to Present at the Noble Financial Equity Conference
4. STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification
5. STAAR Surgicals LASIK Alternative Expands U.S. Market Gains
6. STAAR Surgical Reports Solid First Quarter Progress
7. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
8. STAAR Surgical Plans Major Presence at ASCRS
9. STAAR Surgical Reports Fourth Quarter and Year End Results
10. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
11. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
(Date:2/12/2016)... PITTSBURGH, Pa. (PRWEB) , ... February 12, 2016 , ... ... space heaters. , This winter the West Penn Burn Center, part of ... Fire Company #1, to bring you the “Space Heaters Need Space” campaign. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Vail knee ... Industry Physician Leaders to Know in 2016 . The list consists of physicians establishing, ... physicians to establish this list. , An Ambulatory Surgery Center, also known as ...
(Date:2/12/2016)... FLA (PRWEB) , ... February 12, 2016 , ... Miami ... dental implants to their Miami dental office. Beginning in January, Miami Dental Specialists ... titanium. Miami Dental Specialists are the first office to be chosen by the dental ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... foods choices that promote eye health. These articles generally list between five and ... health advocate Sharon Kleyne endorses every one of these lists and believes that ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... (NasdaqCM: PDEX) today announced financial results for its fiscal 2016 ... its Quarterly Report on Form 10-Q for the second quarter ... today. --> --> Quarter ... --> Net sales for the three months ended December ... from $2.8 million for the three months ended December 31, ...
(Date:2/11/2016)... -- Governor Andrew M. Cuomo today announced a major expansion ... Western New York . This announcement, made ... includes a major expansion of Athenex,s North American headquarters ... , as well as the creation of a state-of-the-art, ... . The combined projects are expected to yield ...
Breaking Medicine Technology: